Αρχίζει αύριο η Real time παρακολούθηση των πωλήσεων φαρμάκων από τον ΕΟΦ

Νέες “φωτιές άναψε” στις Φαρμακευτικές Επιχειρήσεις ο ΕΟΦ, ανακοινώνοντας, την αλλαγή της διαδικασίας υποβολής των στοιχείων των πωλήσεων των φαρμακευτικών προϊόντων εντός δύο ημερών!

Προκειμένου να τεθούν “οι φωτιές” υπό έλεγχο και να αποφευχθούν σοβαρά λάθη, η Φαρμακοβιομηχανία ετοιμάζεται, σύμφωνα να ζητήσει παράταση…

Η απόφαση αυτή, που θα επιτρέψει την παρακολούθηση των στοιχείων πωλήσεων των φαρμακευτικών προϊόντων σε πραγματικό χρόνο (real time), καθώς θα πρέπει να υποβάλλονται, μέσω μιας νέας  διαδικτυακής εφαρμογής, το αργότερο εντός 48 ωρών από την έκδοση του σχετικού Τιμολογίου – ∆ελτίου Αποστολής, χαρακτηρίζεται ως θετική από στελέχη της Φαρμακοβιομηχανίας.

How 3D printing will change the pharmaceutical world forever

 Insider | Eugene Borukhovich 

New possibilities in 3D printing may open up a whole new chapter of opportunities for pharmaceutical research and bio-technology applications. There are a number of ways it could be used — drug dosage forms, supporting delivery, or helping to research cures. Let’s explore how that might work.

3D printing has been around for many years; predominantly been used in manufacturing. This type of printing, also called stereolithography, can create almost any object by fusing different materials, layer by layer, to form a physical version of a digital 3D image. Over the past 15 years, 3D printing has expanded into the healthcare industry, where it’s used to create custom prosthetics and dental implants. Now, there may be an opportunity to use it for personalized healthcare as well.

Pharmaceutical drug research and development could be improved drastically by 3D printing. Rather than printing objects made out of plastic or metal, imagine printing pills or human organs and tissue. This would allow companies to test drugs much more safely (and much cheaper). It seems to be within science’s reach — and closer than ever.

Healthcare changes on the horizon

Compared to other sectors, 3D printing technology has played a minor role in healthcare so far. Experts assume that healthcare only accounted for 1.6 percent of all investments made into the $700 million 3D printing industry. However, that number is expected to grow to 21 percent over the next 10 years.

The most influential people in biopharma today

Biopharma is in for a transformational year in 2016. Lawmakers are clamoring for drug price reform. Patients are protesting for faster FDA approvals. Patents are under fire from value-seeking hedge funders. And the industry's least-welcome spokesman is live-streaming the whole thing.

This year, some of the fundamental pillars of the industry suddenly seem vulnerable. The rise of biosimilars is poised to cut into pharma's cash reserves, while the once-reliable demand for biotech IPOs has all but dried up. What makes a drug approvable is the subject of a newly heated debate, while the financial wizardry that once made drug companies a sure bet has come under intense scrutiny.

We've put together a list of the people in and around biopharma who are poised to play major roles in the industry's evolution. Some are recent hires hoping to rescue moribund giants, while others are long-tenured veterans trying to steer their firms into brighter futures.

Each is facing a make-or-break 2016 with wide implications for the drug business as a whole.

Can Ian Read's Pfizer ($PFE) deliver on its big goals after a record-breaking merger? How will John Milligan keep Gilead Sciences ($GILD) rolling when its blockbusters plateau? 

Can Anne Wojcicki complete 23andMe's turnaround? And will Martin Shkreli stay out of prison long enough to start another company?

THE CORPORATE REPUTATION OF THE PHARMACEUTICAL INDUSTRY IN 2015

London, March 10th, 2016. 

This report is based on the findings of a Patient View November 2015-January 2016 survey exploring the views of 1,075 patient groups from 72 countries, and focusing on differing medical specialties. The report provides feedback on the corporate reputation of the pharma industry during 2015, as well as the performance of 48 pharma companies for six key indicators that influence corporate reputation. Results are compared with those of the previous four years.

For the purposes of this report, the phrase ‘corporate reputation’ is defined as the extent to which pharma companies are meeting the expectations of patients and patient groups.

The six indicators of corporate reputation:

1. Patient-centricity.
2. Patient information.
3. Patient safety.
4. Useful products.
5. Transparency; and
6. Integrity

The 48 companies analysed:

AbbVie I Actavis I Allergan I Almirall I Amgen I Astellas Pharma I AstraZeneca I Baxalta I Bayer I Biogen Idec I Boehringer Ingelheim I Bristol-Myers Squibb I Celgene I Chiesi Farmaceutici I Eisai I Eli Lilly (Lilly) I Ferring I Gedeon Richter I Gilead Sciences I Grifols I Grünenthal I GSK I Hospira I Ipsen I Janssen Pharmaceutical Companies of Johnson & Johnson I LEO Pharma I Lundbeck I Mallinckrodt I Menarini I Merck & Co I Merck KGaA I Mylan I Novartis I Novo Nordisk I Octapharma I Otsuka I Pfizer I Roche I Sandoz I Sanofi I Servier I Shire I Stada Arzneimittel I Takeda I Teva I UCB I Valeant I ViiV Healthcare

Teva plots global rebrand as it prepares to join hands with Allergan's generics unit

Teva Pharmaceutical Industries Ltd. announced that it is embarking on a strategic enterprise-wide corporate identity program to build a global brand. This is the manifestation of the journey Teva embarked on two years ago, to differentiate itself based on the unique characteristics of the Company's business model and create a new breed of healthcare company.
Teva, the world's leading producer of medicines, is building on its strong global footprint, size and scale, to reinforce its focus on making these medicines more accessible. The company is taking this opportunity to reaffirm its commitment to placing people at its core to enable as many as possible to live better, healthier days.